Journal: Communications Biology
Article Title: MIF downregulation attenuates neuroinflammation via TLR4/MyD88/TRAF6/NF-κB pathway to protect dopaminergic neurons in Parkinson’s disease model
doi: 10.1038/s42003-025-08997-7
Figure Lengend Snippet: a The expressions of TLR4, MyD88, TRAF6, p-p65, p65, p-IκBαand IκBαin the midbrain of mice were detected by Western blotting. b –f Quantitative statistical analysis of the band density of TLR4, MyD88, TRAF6, p-p65/p65 and p-iκBα/IκBα, respectively. n = 3 per group in animal experiments. g Using specific inhibitor ISO-1 or MIF-siRNA, downregulation of MIF inhibits TLR4 receptor activation, thereby inhibiting the MyD88-dependent pathway-mediated pathway downstream of TLR4 and reducing nuclear translocation of the transcription factor NF-κBp65, thereby reducing pro-inflammatory factors (IL-1β, IL-6, TNF-α) transcriptional upregulation to alleviate neuroinflammation and ultimately protect dopaminergic nerves from microglia activation-induced neurological damage and degeneration. All data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA (NS: not statistically significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Article Snippet: MIF inhibitor, (S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1, HY-16692) and Resatorvid (Toll-like receptor 4 inhibitor, HY-11109) were purchased from MedChemExpress.
Techniques: Western Blot, Activation Assay, Translocation Assay